Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2022 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

LEXINGTON, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
February 11, 2022 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
January 31, 2022 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

LEXINGTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
December 13, 2021 16:05 ET | Source: Keros Therapeutics, Inc.

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

Lexington, Mass. – December 13, 2021 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors under the heading "A Phase...
December 13, 2021 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China

Keros Therapeutics to receive potential milestone payments up to $170.5 million, $20 million upfront, and tiered royalty payments in the low double digit to high teens on net product sales LEXINGTON,...
November 22, 2021 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

LEXINGTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
November 15, 2021 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
November 11, 2021 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

LEXINGTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
November 08, 2021 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions

LEXINGTON, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
November 04, 2021 09:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...